image-title

Mission Statement:

Bassett Medical Center is a part of Bassett Healthcare Network, a healthcare system that strives to provide excellence in healthcare to rural communities across eight counties in central New York. Bassett Medical Center is an academic medical center that exists to offer a continuum of care for our patients in all service lines, while advancing the healthcare of rural populations through educating physicians and other healthcare professionals and pursuing health research. Continue reading Bassett Healthcare Network Bassett Medical Center

Read More

(Excerpt from drugchannels.net) Patients today are being asked to pay a significant share of prescription costs for more-expensive specialty drugs, because of high coinsurance amounts. Many patients also face a deductible for their prescriptions.These are either a combined medical-pharmacy benefit deductible or an annual prescription drug deductible that was separate from any general annual deductible.
Copayment offset programs (also called copay cards or coupons) have traditionally covered a beneficiary’s out-of-pocket costs and/or deductible for a brand-name specialty drug.
For the 2018 benefit plan year, however, many plan sponsors are adopting a copay accumulator approach that alters the conventional scenario. The impact is significant for cancer patients needing assistance to pay for pharmaceutical therapies.
Here are 3 articles to learn more about this industry trend and a download to the NCODA CoPay Accumulator brochure to help educate your patients as they manage the financial impact of copay accumulator programs.
Read More

PRINCETON, N.J., June 7, 2018 – Taiho Oncology, Inc. today announced that, in an effort to further support access for patients and their LONSURF® treatment, the co-pay for all dose strengths of LONSURF has been reduced from $30 to $0 per treatment cycle. The co-pay reduction, which took effect on May 1, 2018, is available to all patients with commercial prescription insurance coverage for LONSURF.
Read More
RealGiDo study results showed median time on treatment and time to progression of 18.7 and 20.8 months, respectively, were not impacted by dose modifications with Gilotrif® (afatinib) as first-line therapyGilotrif safety profile observed in real-world setting showed that there were no new safety signals
Ridgefield, Conn., May 31, 2018 – Boehringer Ingelheim today announced results from a retrospective, observational real-world study assessing the impact of dose adjustments of Gilotrif® (afatinib) on safety and efficacy in patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC). The study showed that dose adjustment with Gilotrif helped improve patient tolerability while maintaining treatment efficacy and reduced the frequency and intensity of drug reactions. These findings, which were consistent with clinical trials, were published online by the American Society of Clinical Oncology (ASCO) n advance of its 2018 annual conference. Read article .
Read More